| Project/Area Number |
24791382
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | National Hospital Organization, Kyushu Cancer Center (2013)
Nagasaki University (2012) |
|---|
Principal Investigator |
OIKAWA Masahiro 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 乳腺科フェロー (90612416)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ゲノム不安定性 / 乳癌 / アレイCGH / 染色体構造変化 / 腫瘍内不均一性 / breast cancer / genome instability / array CGH / FFPE / 乳腺腫瘍 / 診断 |
|---|
| Research Abstract |
High risk patients among ER-positive/HER2-negative breast cancer can be stratified by intra-tumoral heterogeneity as a surrogate marker for genomic instability. The double-stranded DNA ratio of tumor DNA predicted the performance of DNA from FFPE samples on the aCGH analysis. Quality control by this metrics can utilize valuable FFPE archival tissue on aCGH analysis. our novel diagnostic method, which targets genomic instability, can clearly distinguish cancers from benign tumors of breast intracystic lesions with minimum invasion, thereby avoiding the need for surgical excisional biopsy. Novel therapeutic strategy targeting genomic instability in breast cancer, which is dual administration of Olaparib and Gimeracil, showed growth inhibition of breast cancer cell line with high genomic instability.
|
